Pulse Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
Pulse Biosciences, Inc. filed this Current Report on Form 8-K on November 14, 2016. The filing serves to announce financial results for the third fiscal quarter ended September 30, 2016. The company is incorporated in Nevada and maintains its principal executive offices in Burlingame, California.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document acts as a notification that these results were announced via a press release (Exhibit 99.1) but does not reproduce the financial data within the body of the 8-K itself.
Material Changes
The filing references a "Quarterly Nano-Pulse Stimulation (NPS) Update" in the associated press release. However, the text of this Form 8-K does not detail specific material changes in financial condition or operations compared to prior periods.
Guidance, Outlook, and Risks
Management commentary, forward-looking guidance, specific risks, and contingencies are not detailed in this filing text. The document explicitly states that the press release (Exhibit 99.1) is furnished and not filed for purposes of Section 18 of the Exchange Act, meaning the detailed operational updates are contained in the exhibit rather than the main report.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q3 2016 revenue and net loss figures.
- Verify the status and clinical progress of the Nano-Pulse Stimulation (NPS) technology mentioned in the update.
- Check the company's cash position and runway as detailed in the full quarterly report.
- Confirm if there were any changes in the company's capital structure or debt obligations during the quarter.